Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

Insulin and syringe | Image Credit: © Sherry Young - stock.adobe.com
Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

July 15th 2025

The agent, Kirsty, represents a more affordable alternative to Novolog.

ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology
ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology

July 14th 2025

ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access

July 10th 2025

Pediatric patient with IBD-related pain -- Image credit: Khunatorn | stock.adobe.com
Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds

July 8th 2025

Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
Real-World Data Show Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

July 4th 2025

Video Interviews
Podcasts

More News